Twist Bioscience FY26 Q3 adjusted EBITDA loss narrows to $(11.3) million; revenue rises 23% YoY to $118.4 million
TWST•Segment performance
- DNA synthesis and protein solutions revenue climbed 39% year over year to $56.6 million, with about 369,000 genes shipped.
- NGS applications revenue increased 12% year over year to $61.8 million, with growth led by diagnostic customers.
Quarterly revenue and profitability
- Twist Bioscience posted fiscal third-quarter revenue of $118.4 million, up 23% year over year, beating guidance of $114 million-$115 million.
- Gross margin rose to 52.8%, up about 120 basis points sequentially from fiscal second quarter.
- Adjusted EBITDA loss narrowed to $11.3 million as the company said it is on track for breakeven in fiscal fourth quarter.
Related News
FDA Provides Further Regulatory Guidance To Acurx Pharmaceuticals For The Ibezapolstat Clinical Development Program
ACXP•
Candel Therapeutics to present extended Phase 3 data on aglatimagene besadenovec in localized prostate cancer at ASTRO 2026
CADL•
